Protein kinase N family (PKN)

The Protein Kinase N (PKN) family, comprising PKN1, PKN2, and PKN3, are serine/threonine kinases that function as key effectors of Rho GTPases (UniProt P17612, Q16513, Q6P5Z2). They are characterized by N-terminal HR1 repeats that mediate binding to RhoA, RhoB, and RhoC, thereby regulating cytoskeleton organization, cell migration, and gene expression (Flynn et al., 2011). PKN isoforms are implicated in various pathologies, particularly oncology; PKN1 acts as a co-activator for the androgen receptor in prostate cancer, while PKN3 is a critical mediator of tumor angiogenesis and metastasis (Leenders et al., 2004; Metzger et al., 2003). PKN2 has been shown to be essential for cytokinesis and cell-cell adhesion, making it a potential target in proliferative diseases (Schmidt et al., 2007). Therapeutic targeting of the PKN family is an active area of research, with the siRNA-based drug Atu027 having reached clinical trials for advanced solid tumors (Silence Therapeutics). Additionally, small molecules like midostaurin have been identified as potent inhibitors of PKN1, highlighting the potential for pharmacological intervention in PKN-driven diseases (PMID: 25824331). Challenges in targeting this family include achieving isoform selectivity and avoiding off-target effects on other AGC kinases like PKC or AKT (Pearce et al., 2010). Overall, the PKN family represents a significant node in Rho-dependent signaling with high therapeutic potential in cancer and potentially cardiovascular disorders.

Other names

Protein kinase C-related kinasePRK familyPKN1PKN2PKN3PRK1PRK2PRK3

Inhibition of serine/threonine kinase activity through ATP-competitive small molecules or reduction of protein expression via RNA interference (siRNA).